Effect of oral administration of in silico epitope-based SARS-CoV-2 virus with ISCOM adjuvants on increasing the number of NK cells and serum IgG in mice
Main Article Content
Keywords
epitope, in silico, IgG, NK cells, SARS-CoV-2
Abstract
Background: Vaccines are one of the best solutions to deal with the COVID-19 pandemic. Epitope vaccines can be searched in silico. The selection of in silico epitope-based SARS-CoV-2 which is used as a vaccine candidate must be able to trigger an immune response, such as proteins from the spike (S), envelope (E), membrane (M) in SARS-CoV-2. This study aims to determine the potential for in silico epitope-based SARS-CoV-2 from S, EM, and SEM which is immunogenic, non-toxic, and non-allergenic. And evaluate the immune response by measuring the number of NK cells in the spleen and serum IgG levels in mice.
Method: This research was carried out in 2 stages, an in silico exploratory study and an experimental study. The exploratory stage consisted of selecting immunogenic, non-toxic, non-allergic vaccine candidates, molecular docking tests, and epitope conjugation with an adjuvant in the form of ISCOM which was observed with a TEM microscope. The first group was the control, and the second group was given ISCOM. The remaining groups were each given the S, EM, and SEM epitope which had been conjugated with ISCOM and all were given orally. In 5 groups, NK cell levels were measured using a flow cytometer, while IgG levels were measured using Elisa.
Research: The results of the in-silico test showed that 3 epitopes of S (FLVLLPLVSSQCVN), E (VNSVLLFLAFVVFLLVTLASS), and M (LYIIKLIFLWLLWPVTLACFV-LAAVY) were immunogenic, non-toxic, and non-allergic. Oral administration of in silico epitope-based SARS-CoV-2 in mice could increase the highest number of NK cells in the administration of S epitope. Meanwhile, the highest serum IgG level was given with the combination of SEM epitope.
Conclusion: Oral administration of an in-silico epitope based on SARS-CoV-2 from spike, envelope, and membrane can increase the number of NK cells in the spleen and IgG levels in mice.
References
2. Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020/05/04. 2020;145:104236. Available from: https://pubmed.ncbi.nlm.nih.gov/32376359
3. Bao C, Tao X, Cui W, Hao Y, Zheng S, Yi B, et al. Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients. Exp Hematol Oncol. 2021;10(1):5. Available from: https://pubmed.ncbi.nlm.nih.gov/33504359
4. Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010/10/07. 2010;26(23):2936–43. Available from: https://pubmed.ncbi.nlm.nih.gov/20934990
5. Mishra NK, Singla D, Agarwal S, Raghava GPS. ToxiPred: A Server for Prediction of Aqueous Toxicity of Small Chemical Molecules in <I>T.</I> <I>Pyriformis</I> Journal of Translational Toxicology. 2014;1(1):21–7. Available from: http://dx.doi.org/10.1166/jtt.2014.1005
6. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Consortium OSDD, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957–e73957. Available from: https://pubmed.ncbi.nlm.nih.gov/24058508
7. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2013;30(6):846–51. Available from: http://dx.doi.org/10.1093/bioinformatics/btt619
8. Joshi A, Joshi BC, Mannan MA-U, Kaushik V. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach. Inform Med Unlocked. 2020/04/29. 2020;19:100338. Available from: https://pubmed.ncbi.nlm.nih.gov/32352026
9. Hardjono S, Siswodihardjo S, Pramono P, Darmanto W. Quantitative Structure-Cytotoxic Activity Relationship 1-(Benzoyloxy)urea and Its Derivative. Curr Drug Discov Technol. 2016;13(2):101–8. Available from: https://pubmed.ncbi.nlm.nih.gov/27222144
10. Mowat AMI, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, et al. CTA1-DD-Immune Stimulating Complexes: a Novel, Rationally Designed Combined Mucosal Vaccine Adjuvant Effective with Nanogram Doses of Antigen. The Journal of Immunology. 2001;167(6):3398–405. Available from: http://dx.doi.org/10.4049/jimmunol.167.6.3398
11. Shalash AO, Hussein WM, Skwarczynski M, Toth I. Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. Adv Sci (Weinh). 2021/06/27. 2021;8(16):e2100985–e2100985. Available from: https://pubmed.ncbi.nlm.nih.gov/34176237
12. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009/02/09. 2009;7(3):226–36. Available from: https://pubmed.ncbi.nlm.nih.gov/19198616
13. Von Holle TA, Moody MA. Influenza and Antibody-Dependent Cellular Cytotoxicity. Front Immunol. 2019;10:1457. Available from: https://pubmed.ncbi.nlm.nih.gov/31316510
14. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2020/12/18. 2021;21(2):73–82. Available from: https://pubmed.ncbi.nlm.nih.gov/33340022